Literature DB >> 15800084

A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2.

K J Looker1, G P Garnett.   

Abstract

OBJECTIVES: To explore epidemiological evidence about the interaction of herpes simplex virus (HSV) 1 and HSV-2 infections.
METHODS: A systematic review was undertaken of published epidemiological studies describing the pattern of HSV-1 or HSV-2 by age, and the coincidence of the two viral infections.
RESULTS: In cross sectional studies the unadjusted odds of HSV-2 are greater in those with HSV-1 infection in study populations categorised as "low risk" (p = 0.06) and across European populations (p = 0.001). This was not evident in "high risk" populations or in the United States. This increased risk of HSV-2 in those with HSV-1 infection does not agree with the results of prospective studies where there is a non-significant trend towards a lower risk of HSV-2 infection associated with previous HSV-1 infection.
CONCLUSIONS: "Low risk" and European populations have a relatively low HSV-2 seroprevalence and infection is more concentrated in those with characteristics putting them at high risk for both HSV-1 and HSV-2. This confounding could mask any protective effect of HSV-1, which is hinted at, but not demonstrated, in prospective and adjusted studies.

Entities:  

Mesh:

Year:  2005        PMID: 15800084      PMCID: PMC1764655          DOI: 10.1136/sti.2004.012039

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  35 in total

1.  Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany.

Authors:  H F Rabenau; S Buxbaum; W Preiser; B Weber; H W Doerr
Journal:  Med Microbiol Immunol       Date:  2002-03       Impact factor: 3.402

2.  Prevalence of herpes simplex virus type 2 antibody in Cameroon.

Authors:  Anna Maria Eis-Hübinger; Emmanuel Nyankiye; Didier Mboua Bitoungui; Jean Ndjomou
Journal:  Sex Transm Dis       Date:  2002-11       Impact factor: 2.830

3.  Ethnic variation in type of genital herpes simplex virus infection in a South London genitourinary medicine clinic.

Authors:  M Strutt; J Bailey; M Tenant-Flowers; D Graham; M Zuckerman
Journal:  J Med Virol       Date:  2003-01       Impact factor: 2.327

4.  Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994.

Authors:  Fujie Xu; Julia A Schillinger; Maya R Sternberg; Robert E Johnson; Francis K Lee; Andre J Nahmias; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2002-03-22       Impact factor: 5.226

5.  Proportion of herpes simplex virus (HSV) type 1 and type 2 among genital and extragenital HSV isolates.

Authors:  Gun-Britt Löwhagen; Petra Tunbäck; Tomas Bergström
Journal:  Acta Derm Venereol       Date:  2002       Impact factor: 4.437

6.  Seroprevalence of antibodies to herpes simplex virus types 1 and 2 among two sexually active female populations in Middlesbrough, England.

Authors:  A A Opaneye; J Bashford
Journal:  J R Soc Promot Health       Date:  2002-06

7.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

8.  Genital shedding of herpes simplex virus among men.

Authors:  Anna Wald; Judith Zeh; Stacy Selke; Terri Warren; Rhoda Ashley; Lawrence Corey
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

Review 9.  Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review.

Authors:  Jennifer S Smith; N Jamie Robinson
Journal:  J Infect Dis       Date:  2002-10-15       Impact factor: 5.226

10.  Helicobacter pylori prevalence among indigenous peoples of South America.

Authors:  Lisa-Gaye E Robinson; Francis L Black; Francis K Lee; Alexandra O Sousa; Marilyn Owens; Dan Danielsson; André J Nahmias; Benjamin D Gold
Journal:  J Infect Dis       Date:  2002-09-20       Impact factor: 5.226

View more
  55 in total

1.  Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions.

Authors:  Talía Malagón; Philippe Lemieux-Mellouki; Jean-François Laprise; Marc Brisson
Journal:  Am J Epidemiol       Date:  2016-12-07       Impact factor: 4.897

2.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

3.  HSV-2 Seroepidemiology and Risk Factors among Iranian Women: A Time to New Thinking.

Authors:  S Asgari; L Chamani-Tabriz; S Asadi; F Fatemi; H Zeraati; M M Akhondi; A Shahnazi
Journal:  Iran Red Crescent Med J       Date:  2011-11-01       Impact factor: 0.611

4.  Degeneration and regeneration of corneal nerves in response to HSV-1 infection.

Authors:  Ana J Chucair-Elliott; Min Zheng; Daniel J J Carr
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-01-13       Impact factor: 4.799

5.  Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi.

Authors:  Balbina J Plotkin; Ira M Sigar; Vaibhav Tiwari; Scott Halkyard
Journal:  J Vis Exp       Date:  2016-07-06       Impact factor: 1.355

6.  Mucosal erosions as the presenting symptom in erythema multiforme: a case report.

Authors:  Stephen Spencer; Thajunnisha Buhary; Ian Coulson; Sedki Gayed
Journal:  Br J Gen Pract       Date:  2016-03       Impact factor: 5.386

Review 7.  The alpha-herpesviruses: molecular pathfinders in nervous system circuits.

Authors:  Mats I Ekstrand; L W Enquist; Lisa E Pomeranz
Journal:  Trends Mol Med       Date:  2008-02-14       Impact factor: 11.951

8.  Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.

Authors:  Richard Brans; Feng Yao
Journal:  BMC Microbiol       Date:  2010-06-03       Impact factor: 3.605

9.  Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1.

Authors:  Richard Brans; Natali V Akhrameyeva; Feng Yao
Journal:  J Invest Dermatol       Date:  2009-04-09       Impact factor: 8.551

10.  Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Peter D Burbelo; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.